| Sonstiges: |
- Nachgewiesen in: MEDLINE
- Sprachen: English
- Publication Type: Journal Article
- Language: English
- [Phys Eng Sci Med] 2024 Jun; Vol. 47 (2), pp. 741-753. <i>Date of Electronic Publication: </i>2024 Mar 25.
- MeSH Terms: Prostatic Neoplasms* / diagnostic imaging ; Prostatic Neoplasms* / pathology ; Positron Emission Tomography Computed Tomography* ; Machine Learning* ; Gallium Radioisotopes* ; Gallium Isotopes* ; Neoplasm Grading* ; Humans ; Male ; Aged ; Middle Aged ; Image Processing, Computer-Assisted ; ROC Curve ; Edetic Acid / analogs & derivatives ; Oligopeptides / chemistry
- References: Plym A, Zhang Y, Stopsack KH, Delcoigne B, Wiklund F, Haiman C et al (2022) A healthy lifestyle in men at increased genetic risk for prostate cancer. Eur Urol 83:343. (PMID: 356370411027992510.1016/j.eururo.2022.05.008) ; Chung LW, Isaacs WB, Simons JW (2007) Prostate cancer: biology, genetics, and the new therapeutics. Springer Science & Business Media, Totowa. (PMID: 10.1007/978-1-59745-224-3) ; Salam M. Principles and practice of Urology: JP Medical Ltd; 2013. ; Eder M, Schäfer M, Bauder-Wüst U, Hull W-E, Wängler C, Mier W et al (2012) 68Ga-complex lipophilicity and the targeting property of a urea-based PSMA inhibitor for PET imaging. Bioconjug Chem 23(4):688–697. (PMID: 2236951510.1021/bc200279b) ; Beheshti M, Langsteger W, Rezaee A. PET/CT in cancer: an interdisciplinary approach to individualized imaging: Elsevier Health Sciences; 2017. ; Emmett L, Willowson K, Violet J, Shin J, Blanksby A, Lee J (2017) Lutetium 177 PSMA radionuclide therapy for men with prostate cancer: a review of the current literature and discussion of practical aspects of therapy. Journal of medical radiation sciences 64(1):52–60. (PMID: 28303694535537410.1002/jmrs.227) ; Donato P, Morton A, Yaxley J, Ranasinghe S, Teloken PE, Kyle S et al (2020) 68 Ga-PSMA PET/CT better characterises localised prostate cancer after MRI and transperineal prostate biopsy: Is 68 Ga-PSMA PET/CT guided biopsy the future? Eur J Nucl Med Mol Imaging 47:1843–1851. (PMID: 3191225710.1007/s00259-019-04620-0) ; Schmuck S, Nordlohne S, von Klot C-A, Henkenberens C, Sohns JM, Christiansen H et al (2017) Comparison of standard and delayed imaging to improve the detection rate of [68 Ga] PSMA I&T PET/CT in patients with biochemical recurrence or prostate-specific antigen persistence after primary therapy for prostate cancer. Eur J Nucl Med Mol Imaging 44:960–968. (PMID: 2828085610.1007/s00259-017-3669-5) ; Hatt M, Krizsan A, Rahmim A, Bradshaw T, Costa P, Forgacs A et al (2023) Joint EANM/SNMMI guideline on radiomics in nuclear medicine: Jointly supported by the EANM Physics Committee and the SNMMI Physics, Instrumentation and Data Sciences Council. Eur J Nucl Med Mol Imaging 50(2):352–375. (PMID: 3632686810.1007/s00259-022-06001-6) ; Hajianfar G, Haddadi Avval A, Hosseini SA, Nazari M, Oveisi M, Shiri I, Zaidi H (2023) Time-to-event overall survival prediction in glioblastoma multiforme patients using magnetic resonance imaging radiomics. Radiol Med (Torino) 128:1521. (PMID: 3775110210.1007/s11547-023-01725-3) ; Benoit-Cattin H. Texture analysis for magnetic resonance imaging: Texture Analysis Magn Resona; 2006. ; Fusco R, Granata V, Grazzini G, Pradella S, Borgheresi A, Bruno A et al (2022) Radiomics in medical imaging: pitfalls and challenges in clinical management. Jpn J Radiol 40(9):919–929. (PMID: 3534413210.1007/s11604-022-01271-4) ; Lambin P, Rios-Velazquez E, Leijenaar R, Carvalho S, Van Stiphout RG, Granton P et al (2012) Radiomics: extracting more information from medical images using advanced feature analysis. Eur J Cancer 48(4):441–446. (PMID: 22257792453398610.1016/j.ejca.2011.11.036) ; Hajianfar G, Kalayinia S, Hosseinzadeh M, Samanian S, Maleki M, Sossi V et al (2023) Prediction of Parkinson’s disease pathogenic variants using hybrid Machine learning systems and radiomic features. Physica Med 113:102647. (PMID: 10.1016/j.ejmp.2023.102647) ; Alongi P, Stefano A, Comelli A, Laudicella R, Scalisi S, Arnone G et al (2021) Radiomics analysis of 18F-Choline PET/CT in the prediction of disease outcome in high-risk prostate cancer: An explorative study on machine learning feature classification in 94 patients. Eur Radiol 31:4595–4605. (PMID: 3344360210.1007/s00330-020-07617-8) ; Nai Y-H, Cheong DLH, Roy S, Kok T, Stephenson MC, Schaefferkoetter J et al (2023) Comparison of quantitative parameters and radiomic features as inputs into machine learning models to predict the Gleason score of prostate cancer lesions. Magn Reson Imaging 100:64–72. (PMID: 3693377510.1016/j.mri.2023.03.009) ; Zamboglou C, Carles M, Fechter T, Kiefer S, Reichel K, Fassbender TF et al (2019) Radiomic features from PSMA PET for non-invasive intraprostatic tumor discrimination and characterization in patients with intermediate-and high-risk prostate cancer-a comparison study with histology reference. Theranostics 9(9):2595. (PMID: 31131055652599310.7150/thno.32376) ; Zwanenburg A, Vallières M, Abdalah MA, Aerts HJ, Andrearczyk V, Apte A et al (2020) The image biomarker standardization initiative: standardized quantitative radiomics for high-throughput image-based phenotyping. Radiology 295(2):328–338. (PMID: 3215477310.1148/radiol.2020191145) ; Nioche C, Orlhac F, Boughdad S, Reuzé S, Goya-Outi J, Robert C et al (2018) LIFEx: a freeware for radiomic feature calculation in multimodality imaging to accelerate advances in the characterization of tumor heterogeneity. Can Res 78(16):4786–4789. (PMID: 10.1158/0008-5472.CAN-18-0125) ; Shiri I, Amini M, Nazari M, Hajianfar G, Avval AH, Abdollahi H et al (2022) Impact of feature harmonization on radiogenomics analysis: Prediction of EGFR and KRAS mutations from non-small cell lung cancer PET/CT images. Comput Biol Med 142:105230. (PMID: 3505185610.1016/j.compbiomed.2022.105230) ; Hajianfar G, Avval AH, Sabouri M, Khateri M, Jenabi E, Geramifar P, et al., editors. ComBat Harmonization of Image Reconstruction Parameters to Improve the Repeatability of Radiomics Features. 2021 IEEE Nuclear Science Symposium and Medical Imaging Conference (NSS/MIC); 2021: IEEE. ; Johnson WE, Li C, Rabinovic A (2007) Adjusting batch effects in microarray expression data using empirical Bayes methods. Biostatistics 8(1):118–127. (PMID: 1663251510.1093/biostatistics/kxj037) ; Fortin J-P, Parker D, Tunç B, Watanabe T, Elliott MA, Ruparel K et al (2017) Harmonization of multi-site diffusion tensor imaging data. Neuroimage 161:149–170. (PMID: 2882694610.1016/j.neuroimage.2017.08.047) ; Fortin J-P, Cullen N, Sheline YI, Taylor WD, Aselcioglu I, Cook PA et al (2018) Harmonization of cortical thickness measurements across scanners and sites. Neuroimage 167:104–120. (PMID: 2915518410.1016/j.neuroimage.2017.11.024) ; Varghese B, Chen F, Hwang D, Palmer SL, De Castro Abreu AL, Ukimura O, et al., editors. Objective risk stratification of prostate cancer using machine learning and radiomics applied to multiparametric magnetic resonance images. Proceedings of the 11th ACM International Conference on Bioinformatics, Computational Biology and Health Informatics; 2020. ; Du D, Shiri I, Yousefirizi F, Salmanpour MR, Lv J, Wu H et al (2023) Impact of harmonization and oversampling methods on radiomics analysis of multi-center imbalanced datasets: Application to PET-based prediction of lung cancer subtypes. 71:209. ; DeLong ER, DeLong DM, Clarke-Pearson DL (1988) Comparing the areas under two or more correlated receiver operating characteristic curves: a nonparametric approach. Biometrics 44:837–845. (PMID: 320313210.2307/2531595) ; Fendler WP, Eiber M, Beheshti M, Bomanji J, Calais J, Ceci F et al (2023) PSMA PET/CT: joint EANM procedure guideline/SNMMI procedure standard for prostate cancer imaging 2.0. Eur J Nucl Med Mol Imaging 50(5):1466–1486. (PMID: 366043261002780510.1007/s00259-022-06089-w) ; Dehm SM, Tindall DJ (2020) Prostate Cancer: Cellular and Genetic Mechanisms of Disease Development and Progression. Springer Nature, Cham. ; Yu AC, Eng J (2020) One algorithm may not fit all: how selection bias affects machine learning performance. Radiographics 40(7):1932–1937. (PMID: 3297606210.1148/rg.2020200040) ; Shiri I, Salimi Y, Pakbin M, Hajianfar G, Avval AH, Sanaat A et al (2022) COVID-19 prognostic modeling using CT radiomic features and machine learning algorithms: Analysis of a multi-institutional dataset of 14,339 patients. Comput Biol Med 145:105467. (PMID: 35378436896401510.1016/j.compbiomed.2022.105467) ; Orlhac F, Eertink JJ, Cottereau A-S, Zijlstra JM, Thieblemont C, Meignan M et al (2022) A guide to ComBat harmonization of imaging biomarkers in multicenter studies. J Nucl Med 63(2):172–179. (PMID: 34531263880577910.2967/jnumed.121.262464) ; Nieri A, Manco L, Bauckneht M, Urso L, Caracciolo M, Donegani MI et al (2023) [18F] FDG PET-TC radiomics and machine learning in the evaluation of prostate incidental uptake. Expert Rev Med Devices 20(12):1183–1191. (PMID: 3794263010.1080/17434440.2023.2280685) ; Yaxley JW, Raveenthiran S, Nouhaud F-X, Samartunga H, Yaxley AJ, Coughlin G et al (2019) Outcomes of primary lymph node staging of intermediate and high risk prostate cancer with 68Ga-PSMA positron emission tomography/computerized tomography compared to histological correlation of pelvic lymph node pathology. J Urol 201(4):815–820. (PMID: 3067284210.1097/JU.0000000000000053) ; Leung KH, Rowe SP, Leal JP, Ashrafinia S, Sadaghiani MS, Chung HW et al (2022) Deep learning and radiomics framework for PSMA-RADS classification of prostate cancer on PSMA PET. EJNMMI Res 12(1):1–15. (PMID: 10.1186/s13550-022-00948-1) ; Japkowicz N, Stephen S (2002) The class imbalance problem: A systematic study. Intelligent data analysis 6(5):429–449. (PMID: 10.3233/IDA-2002-6504) ; Papp L, Spielvogel C, Grubmüller B, Grahovac M, Krajnc D, Ecsedi B et al (2021) Supervised machine learning enables non-invasive lesion characterization in primary prostate cancer with [68 Ga] Ga-PSMA-11 PET/MRI. Eur J Nucl Med Mol Imaging 48:1795–1805. (PMID: 3334191510.1007/s00259-020-05140-y) ; Cysouw MC, Jansen BH, van de Brug T, Oprea-Lager DE, Pfaehler E, de Vries BM et al (2021) Machine learning-based analysis of [18 F] DCFPyL PET radiomics for risk stratification in primary prostate cancer. Eur J Nucl Med Mol Imaging 48:340–349. (PMID: 3273751810.1007/s00259-020-04971-z) ; Mofrad FB, Zoroofi RA, Tehrani-Fard AA, Akhlaghpoor S, Sato Y (2014) Classification of normal and diseased liver shapes based on spherical harmonics coefficients. J Med Syst 38:1–9. (PMID: 10.1007/s10916-014-0020-6) ; Davnall F, Yip CS, Ljungqvist G, Selmi M, Ng F, Sanghera B et al (2012) Assessment of tumor heterogeneity: an emerging imaging tool for clinical practice? Insights Imaging 3:573–589. (PMID: 23093486350556910.1007/s13244-012-0196-6) ; Chen X, Oshima K, Schott D, Wu H, Hall W, Song Y et al (2017) Assessment of treatment response during chemoradiation therapy for pancreatic cancer based on quantitative radiomic analysis of daily CTs: An exploratory study. PLoS ONE 12(6):e0178961. (PMID: 28575105545636510.1371/journal.pone.0178961) ; Qiu Q, Duan J, Yin Y (2020) Radiomics in radiotherapy: applications and future challenges. Precision Radiation Oncol 4(1):29–33. (PMID: 10.1002/pro6.1087) ; Dong X, Sun X, Sun L, Maxim PG, Xing L, Huang Y et al (2016) Early change in metabolic tumor heterogeneity during chemoradiotherapy and its prognostic value for patients with locally advanced non-small cell lung cancer. PLoS ONE 11(6):e0157836. (PMID: 27322376491390310.1371/journal.pone.0157836) ; Solari EL, Gafita A, Schachoff S, Bogdanović B, Villagrán Asiares A, Amiel T et al (2022) The added value of PSMA PET/MR radiomics for prostate cancer staging. Eur J Nucl Med Mol Imaging 49(2):527–538. (PMID: 3425513010.1007/s00259-021-05430-z) ; Krajnc D, Spielvogel CP, Grahovac M, Ecsedi B, Rasul S, Poetsch N et al (2022) Automated data preparation for in vivo tumor characterization with machine learning. Front Oncol 12:1017911. (PMID: 36303841959544610.3389/fonc.2022.1017911) ; Hambarde P, Talbar S, Mahajan A, Chavan S, Thakur M, Sable N (2020) Prostate lesion segmentation in MR images using radiomics based deeply supervised U-Net. Biocybernetics Biomed Eng 40(4):1421–1435. (PMID: 10.1016/j.bbe.2020.07.011) ; Gong L, Xu M, Fang M, He B, Li H, Fang X et al (2022) The potential of prostate gland radiomic features in identifying the Gleason score. Comput Biol Med 144:105318. (PMID: 3524569810.1016/j.compbiomed.2022.105318) ; Peng Y, Shen D, Liao S, Turkbey B, Rais-Bahrami S, Wood B et al (2015) MRI-based prostate volume-adjusted prostate-specific antigen in the diagnosis of prostate cancer. J Magn Reson Imaging 42(6):1733–1739. (PMID: 25946664630107410.1002/jmri.24944) ; Karademir I, Shen D, Peng Y, Liao S, Jiang Y, Yousuf A et al (2013) Prostate volumes derived from MRI and volume-adjusted serum prostate-specific antigen: correlation with Gleason score of prostate cancer. AJR Am J Roentgenol 201(5):1041. (PMID: 24147475435469510.2214/AJR.13.10591) ; Bai W, Fadil Y, Idrissi O, Dakir M, Debbagh A, Abouteib R (2021) The correlation between the gleason score of the biopsy and that of the prostatectomy patch. Annals Med Surg 63:102169. (PMID: 10.1016/j.amsu.2021.02.015) ; Shiri I, Amini M, Yousefirizi F, Vafaei Sadr A, Hajianfar G, Salimi Y et al (2023) Information fusion for fully automated segmentation of head and neck tumors from PET and CT images. Med Phys 51:319. (PMID: 3747559110.1002/mp.16615)
- Contributed Indexing: Keywords: Feature Selection; Ga-PSMA; PET/CT; Prostate Cancer (PCa); Radiomics
- Substance Nomenclature: 0 (Gallium Radioisotopes) ; 0 (Gallium Isotopes) ; 0 (gallium 68 PSMA-11) ; 9G34HU7RV0 (Edetic Acid) ; 0 (Oligopeptides)
- Entry Date(s): Date Created: 20240325 Date Completed: 20240611 Latest Revision: 20240611
- Update Code: 20240611
|
